Compared to 111 VTE controls not taking TT (VTE-no TT), the 67 and 21 cases were more likely (<i>p</i> < 0.05 for all) to have Factor V Leiden (FVL) heterogeneity (24% and 33% vs. 12%), the lupus anticoagulant (14% and 33% vs. 4%), and high lipoprotein(a) (33% vs. 13%, <i>n</i> = 21).
The symptoms resolved dramatically by treatment with the combination of immunosuppression and anticoagulation with regard to the detected factor V Leiden mutation and high lipoprotein(a) level.
In prothrombotic screening studies she and her father were both found to be heterozygous for factor V Leiden mutation along with having elevated levels of lipoprotein(a).
The risk profile of advanced atherogenesis further includes cigarette smoking, high lipoprotein(a), the factor V Leiden mutation, low antithrombin III, high fibrinogen, and diabetes.
Comparing women with obstetrical complications versus controls, factor V Leiden mutation was present in 7 (10%) versus 1 (2%) P =.064, odds ratio (OR) = 7, 95%, CI = 0.8-58.5, antiphospholipid antibody syndrome in 14 (19%) versus 2 (3%) P =.003, OR = 7, 95% CI = 1.7-35, high lipoprotein A levels 13 (30%) versus 6 (10%) P =.019, OR = 3.8, 95% CI = 1.3-11.
Assays for the detection of factor-V Leiden mutation and the plasma concentrations of protein C, protein S, antithrombin III, and lipoprotein (a) were performed on plasma samples from children with Legg-Perthes disease, and the results were compared with those for pooled plasma from normal controls.